Cargando…

Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care

Introduction: Real-world data indicate disparities in biologic access across Europe. Objectives: To describe the national structure of PsA care in Poland, with a particular focus on the population of inadequate responders (IRs) and difficulties associated with biologic therapy access. Methods: A poo...

Descripción completa

Detalles Bibliográficos
Autores principales: Batko, Bogdan, Kucharz, Eugeniusz, Stajszczyk, Marcin, Brzosko, Marek, Samborski, Włodzimierz, Żuber, Zbigniew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465653/
https://www.ncbi.nlm.nih.gov/pubmed/34575217
http://dx.doi.org/10.3390/jcm10184106
_version_ 1784572931060269056
author Batko, Bogdan
Kucharz, Eugeniusz
Stajszczyk, Marcin
Brzosko, Marek
Samborski, Włodzimierz
Żuber, Zbigniew
author_facet Batko, Bogdan
Kucharz, Eugeniusz
Stajszczyk, Marcin
Brzosko, Marek
Samborski, Włodzimierz
Żuber, Zbigniew
author_sort Batko, Bogdan
collection PubMed
description Introduction: Real-world data indicate disparities in biologic access across Europe. Objectives: To describe the national structure of PsA care in Poland, with a particular focus on the population of inadequate responders (IRs) and difficulties associated with biologic therapy access. Methods: A pool of rheumatologic and dermatologic care centers was created based on National Health Fund contract lists (n = 841), from which 29 rheumatologic and 10 dermatologic centers were sampled randomly and successfully met the inclusion criterium. Additionally, 33 tertiary care centers were recruited. For successful center recruitment, one provider had to recruit at least one patient that met the criteria for one of the four pre-defined clinical subgroups, in which all patients had to have active PsA and IR status to at least 2 conventional synthetic disease-modifying drugs (csDMARDs). Self-assessment questionnaires were distributed among physicians and their patients. Results: Barriers to biologic DMARD (bDMARD) treatment are complex and include stringency of reimbursement criteria, health care system, logistic/organizational, and personal choice factors. For patients who are currently bDMARD users, the median waiting time from the visit, at which the reimbursement procedure was initiated, to the first day of bDMARD admission was 9 weeks (range 2–212; 32% < 4 weeks, 29% 5–12 weeks, 26% 13–28 weeks, 13% with >28 weeks delay). Out of all inadequate responder groups, bDMARD users are the only group with “good” therapeutic situation and satisfaction with therapy. Patient satisfaction with therapy is not always concordant with physician assessment of therapeutic status. Conclusions: Despite the fact that over a decade has passed since the introduction of biologic agents, in medium welfare countries such as Poland, considerable healthcare system barriers to biologic access are present. Out of different IR populations, patient satisfaction with treatment is often discordant with physician assessment of disease status.
format Online
Article
Text
id pubmed-8465653
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84656532021-09-27 Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care Batko, Bogdan Kucharz, Eugeniusz Stajszczyk, Marcin Brzosko, Marek Samborski, Włodzimierz Żuber, Zbigniew J Clin Med Article Introduction: Real-world data indicate disparities in biologic access across Europe. Objectives: To describe the national structure of PsA care in Poland, with a particular focus on the population of inadequate responders (IRs) and difficulties associated with biologic therapy access. Methods: A pool of rheumatologic and dermatologic care centers was created based on National Health Fund contract lists (n = 841), from which 29 rheumatologic and 10 dermatologic centers were sampled randomly and successfully met the inclusion criterium. Additionally, 33 tertiary care centers were recruited. For successful center recruitment, one provider had to recruit at least one patient that met the criteria for one of the four pre-defined clinical subgroups, in which all patients had to have active PsA and IR status to at least 2 conventional synthetic disease-modifying drugs (csDMARDs). Self-assessment questionnaires were distributed among physicians and their patients. Results: Barriers to biologic DMARD (bDMARD) treatment are complex and include stringency of reimbursement criteria, health care system, logistic/organizational, and personal choice factors. For patients who are currently bDMARD users, the median waiting time from the visit, at which the reimbursement procedure was initiated, to the first day of bDMARD admission was 9 weeks (range 2–212; 32% < 4 weeks, 29% 5–12 weeks, 26% 13–28 weeks, 13% with >28 weeks delay). Out of all inadequate responder groups, bDMARD users are the only group with “good” therapeutic situation and satisfaction with therapy. Patient satisfaction with therapy is not always concordant with physician assessment of therapeutic status. Conclusions: Despite the fact that over a decade has passed since the introduction of biologic agents, in medium welfare countries such as Poland, considerable healthcare system barriers to biologic access are present. Out of different IR populations, patient satisfaction with treatment is often discordant with physician assessment of disease status. MDPI 2021-09-11 /pmc/articles/PMC8465653/ /pubmed/34575217 http://dx.doi.org/10.3390/jcm10184106 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Batko, Bogdan
Kucharz, Eugeniusz
Stajszczyk, Marcin
Brzosko, Marek
Samborski, Włodzimierz
Żuber, Zbigniew
Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care
title Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care
title_full Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care
title_fullStr Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care
title_full_unstemmed Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care
title_short Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care
title_sort real-world data from a multi-center study: insights to psoriatic arthritis care
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465653/
https://www.ncbi.nlm.nih.gov/pubmed/34575217
http://dx.doi.org/10.3390/jcm10184106
work_keys_str_mv AT batkobogdan realworlddatafromamulticenterstudyinsightstopsoriaticarthritiscare
AT kucharzeugeniusz realworlddatafromamulticenterstudyinsightstopsoriaticarthritiscare
AT stajszczykmarcin realworlddatafromamulticenterstudyinsightstopsoriaticarthritiscare
AT brzoskomarek realworlddatafromamulticenterstudyinsightstopsoriaticarthritiscare
AT samborskiwłodzimierz realworlddatafromamulticenterstudyinsightstopsoriaticarthritiscare
AT zuberzbigniew realworlddatafromamulticenterstudyinsightstopsoriaticarthritiscare